Immutep Ltd Hits 52-Week High on Licensing Deal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2025
0mins
Should l Buy IMMP?
Source: 6-K
Immutep Ltd's stock surged by 77.78%, reaching a 52-week high following the announcement of a significant licensing deal.
The company secured an exclusive agreement with Dr. Reddy's for Eftilagimod Alfa, which includes a $20 million upfront payment and potential milestone payments of up to $349.5 million. This strategic collaboration is expected to enhance Immutep's market presence significantly.
The licensing deal not only provides immediate financial benefits but also positions Immutep for future growth in the biopharmaceutical sector, particularly as Eftilagimod Alfa is undergoing a Phase III clinical trial for non-small cell lung cancer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.432
Low
12.00
Averages
12.00
High
12.00
Current: 0.432
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rosen Law Firm Investigates Immutep Securities Fraud Claims
- Securities Fraud Investigation: The Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) for allegedly issuing materially misleading business information, indicating that investors may be entitled to compensation if they purchased Immutep securities.
- Class Action Preparation: The firm is preparing a class action lawsuit aimed at recovering investor losses without requiring any upfront fees, demonstrating a strong commitment to protecting investor rights.
- Stock Price Plunge: On March 13, 2026, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, significantly impacting the company's market value.
- Firm's Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strength and extensive experience in the securities litigation field.
See More
Immutep Faces Investor Misleading Allegations
- Lawsuit Background: On May 5, 2026, a class action was filed against Immutep Limited (IMMP), alleging that the company misled investors regarding the efficacy and viability of its drug candidates between March 24, 2025, and March 12, 2026, resulting in significant investor losses.
- Clinical Trial Issues: The TACTI-004 clinical trial was recommended for discontinuation by the Independent Data Monitoring Committee on March 13, 2026, due to failure to meet primary efficacy and safety endpoints, indicating the company's concealment and misrepresentation of internal clinical data.
- Stock Price Plunge: Following the announcement of the trial's discontinuation, Immutep's ADR price plummeted from $2.76 per share on March 12, 2026, to $0.48 per share, reflecting an 83% decline and severely undermining investor confidence in the company's future prospects.
- Legal Implications: Investors are eligible to submit documents by July 6, 2026, to serve as lead plaintiffs in the class action, highlighting the urgent need for accountability in corporate governance and executive responsibility.
See More
Immutep Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Immutep for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline to contact the firm by July 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Immutep concealed the results of its TACTI-004 trial for eftilagimod alfa, as the company claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: When the market learned the truth about Immutep, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, potentially leading to a decline in investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, highlighting the firm's focus on securities class action lawsuits aimed at helping investors recover losses.
See More
Immutep Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Immutep, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by July 6, 2026, indicating significant legal risks that could impact the company's reputation.
- Trial Discontinuation: On March 13, 2026, Immutep announced the Independent Data Monitoring Committee's recommendation to halt the TACTI-004 Phase III trial, resulting in a major setback for the company’s R&D efforts and potentially affecting future product launch plans.
- Stock Price Plunge: Following the trial discontinuation news, Immutep's American Depositary Receipt (ADR) price fell by $2.27, or 82.44%, closing at $0.48, reflecting the market's pessimistic outlook on the company's future prospects.
- Legal Firm Background: Pomerantz LLP, a leading firm in securities class action litigation with over 85 years of experience, focuses on fighting for the rights of victims of securities fraud, and this lawsuit may prompt increased scrutiny of Immutep's compliance and governance practices.
See More
Immutep Investors Class Action Notice Issued
- Class Action Initiated: The Portnoy Law Firm has launched a class action against Immutep Limited on behalf of investors who purchased securities between March 24, 2025, and March 12, 2026, requiring investors to file a lead plaintiff motion by July 6, 2026, highlighting the firm's commitment to investor rights.
- Basis for Lawsuit: The lawsuit alleges that Immutep concealed the true performance of efti in the TACTI-004 Phase III trial, despite positive efficacy and safety results from other trials, leading investors to make decisions based on misleading information, which adversely affected the company's reputation and stock price.
- Stock Price Plunge: On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 trial based on the Independent Data Monitoring Committee's recommendation, resulting in a more than 82% drop in the company's ADR price, reflecting extreme market pessimism regarding the company's future prospects.
- Legal Support Offered: The Portnoy Law Firm provides complimentary case evaluations and encourages investors to reach out for assistance in recovering losses, demonstrating a strong commitment to supporting affected investors and offering legal recourse.
See More
Immutep Accused of Misleading Investors in Class Action
- Class Action Filed: Robbins LLP reminds all investors who purchased Immutep Limited American Depository Receipts between March 24, 2025, and March 12, 2026, that a class action has been initiated, accusing the company of misleading investors regarding the efficacy and viability of its drug candidate.
- Clinical Trial Issues: The complaint alleges that Immutep concealed critical data regarding the TACTI-004 trial, as despite positive efficacy and safety results in other trials, internal data indicated that the study was at risk of failing to meet its primary efficacy and safety endpoints.
- Stock Price Plummet: On March 13, 2026, Immutep announced that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 trial due to futility, causing its ADR price to plummet from $2.76 to $0.48, a staggering decline of approximately 83%, severely impacting investor confidence.
- Investor Rights Protection: Investors are eligible to submit papers to become lead plaintiffs in the class action by July 6, 2026, with Robbins LLP offering contingency fee representation, ensuring shareholders can recover losses without upfront costs or risks associated with litigation.
See More
Rosen Law Firm Investigates Immutep Securities Fraud Claims
- Securities Fraud Investigation: The Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) for allegedly issuing materially misleading business information, indicating that investors may be entitled to compensation if they purchased Immutep securities.
- Class Action Preparation: The firm is preparing a class action lawsuit aimed at recovering investor losses without requiring any upfront fees, demonstrating a strong commitment to protecting investor rights.
- Stock Price Plunge: On March 13, 2026, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, significantly impacting the company's market value.
- Firm's Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strength and extensive experience in the securities litigation field.
See More
Immutep Faces Investor Misleading Allegations
- Lawsuit Background: On May 5, 2026, a class action was filed against Immutep Limited (IMMP), alleging that the company misled investors regarding the efficacy and viability of its drug candidates between March 24, 2025, and March 12, 2026, resulting in significant investor losses.
- Clinical Trial Issues: The TACTI-004 clinical trial was recommended for discontinuation by the Independent Data Monitoring Committee on March 13, 2026, due to failure to meet primary efficacy and safety endpoints, indicating the company's concealment and misrepresentation of internal clinical data.
- Stock Price Plunge: Following the announcement of the trial's discontinuation, Immutep's ADR price plummeted from $2.76 per share on March 12, 2026, to $0.48 per share, reflecting an 83% decline and severely undermining investor confidence in the company's future prospects.
- Legal Implications: Investors are eligible to submit documents by July 6, 2026, to serve as lead plaintiffs in the class action, highlighting the urgent need for accountability in corporate governance and executive responsibility.
See More
Immutep Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Immutep for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline to contact the firm by July 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Immutep concealed the results of its TACTI-004 trial for eftilagimod alfa, as the company claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: When the market learned the truth about Immutep, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, potentially leading to a decline in investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, highlighting the firm's focus on securities class action lawsuits aimed at helping investors recover losses.
See More
Immutep Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Immutep, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by July 6, 2026, indicating significant legal risks that could impact the company's reputation.
- Trial Discontinuation: On March 13, 2026, Immutep announced the Independent Data Monitoring Committee's recommendation to halt the TACTI-004 Phase III trial, resulting in a major setback for the company’s R&D efforts and potentially affecting future product launch plans.
- Stock Price Plunge: Following the trial discontinuation news, Immutep's American Depositary Receipt (ADR) price fell by $2.27, or 82.44%, closing at $0.48, reflecting the market's pessimistic outlook on the company's future prospects.
- Legal Firm Background: Pomerantz LLP, a leading firm in securities class action litigation with over 85 years of experience, focuses on fighting for the rights of victims of securities fraud, and this lawsuit may prompt increased scrutiny of Immutep's compliance and governance practices.
See More
Immutep Investors Class Action Notice Issued
- Class Action Initiated: The Portnoy Law Firm has launched a class action against Immutep Limited on behalf of investors who purchased securities between March 24, 2025, and March 12, 2026, requiring investors to file a lead plaintiff motion by July 6, 2026, highlighting the firm's commitment to investor rights.
- Basis for Lawsuit: The lawsuit alleges that Immutep concealed the true performance of efti in the TACTI-004 Phase III trial, despite positive efficacy and safety results from other trials, leading investors to make decisions based on misleading information, which adversely affected the company's reputation and stock price.
- Stock Price Plunge: On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 trial based on the Independent Data Monitoring Committee's recommendation, resulting in a more than 82% drop in the company's ADR price, reflecting extreme market pessimism regarding the company's future prospects.
- Legal Support Offered: The Portnoy Law Firm provides complimentary case evaluations and encourages investors to reach out for assistance in recovering losses, demonstrating a strong commitment to supporting affected investors and offering legal recourse.
See More
Immutep Accused of Misleading Investors in Class Action
- Class Action Filed: Robbins LLP reminds all investors who purchased Immutep Limited American Depository Receipts between March 24, 2025, and March 12, 2026, that a class action has been initiated, accusing the company of misleading investors regarding the efficacy and viability of its drug candidate.
- Clinical Trial Issues: The complaint alleges that Immutep concealed critical data regarding the TACTI-004 trial, as despite positive efficacy and safety results in other trials, internal data indicated that the study was at risk of failing to meet its primary efficacy and safety endpoints.
- Stock Price Plummet: On March 13, 2026, Immutep announced that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 trial due to futility, causing its ADR price to plummet from $2.76 to $0.48, a staggering decline of approximately 83%, severely impacting investor confidence.
- Investor Rights Protection: Investors are eligible to submit papers to become lead plaintiffs in the class action by July 6, 2026, with Robbins LLP offering contingency fee representation, ensuring shareholders can recover losses without upfront costs or risks associated with litigation.
See More
